Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (523)	4/15/2005 4:40:25 PM
From: scaram(o)uche	of 933

ASCO...... Sunday, 5/15/2005, 8:00 - 12:00pm Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors Presenter: John L Marshall, MD Developmental Therapeutics: Cytotoxic Chemotherapy Sunday, 5/15/2005, 8:00 - 12:00pm Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors Presenter: J. Paul Monk, MD Developmental Therapeutics: Cytotoxic Chemotherapy Tuesday, 5/17/2005, 8:00 - 12:00pm A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer Presenter: Lorrin Yee Lung Cancer

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next